Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on November 15, 2024. The report discloses a specific corporate event regarding a director's trading plan adopted on November 14, 2024.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 8.01 (Other Events) and contains no financial statements or performance data.
Material Changes
There are no material changes to financial performance or operations reported in this filing. The sole material event is the adoption of a Rule 10b5-1 trading plan by a member of the Board of Directors.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding the company's future business prospects. The only disclosed event is that Anne Altmeyer, Ph.D., a board member, adopted a plan to sell up to 2,452 shares of common stock. The plan allows sales to begin on February 13, 2025, and terminates on December 31, 2025.
Key Facts for Investor Verification
- Director Anne Altmeyer, Ph.D., adopted a Rule 10b5-1 trading plan on November 14, 2024.
- The plan authorizes the sale of up to 2,452 shares of Corbus Pharmaceuticals Holdings, Inc. common stock.
- Sales under the plan may commence on February 13, 2025.
- The trading plan is scheduled to terminate on December 31, 2025.
- No financial results or operational updates are included in this specific filing.